Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Chem. Pharm. Forschungs-Gesellschaft describes COX-2 inhibitors

May 26, 1997

Antibodies to interferon gamma alone and in combination for arthritis and SLE

May 22, 1997

Mylan receives FDA approval for generic etodolac

May 22, 1997

Chiroscience prepares new class of peptidyl MMP and TNF-alpha inhibitors

May 22, 1997

MMP/TNF/CD23 inhibitors prepared by Chiroscience

May 21, 1997

NSAIDS reported by P&G

May 20, 1997

Antiinflammatory imidazolyl compounds from Searle

May 20, 1997

AutoImmune reports preliminary results from phase II trials of Colloral

May 14, 1997

Tularik receives U.S. patent relating to enzyme associated with inflammation

May 14, 1997

Panax to acquire CorBec

May 13, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.